Goatpox, caused by goatpox virus (GTPV), is an acute feverish and contagious disease in goats often associated with high morbidity and high mortality. To resolve potential safety risks and vaccination side effects of existing live attenuated goatpox vaccine (AV41), two Semliki forest virus (SFV) replicon-based bicistronic expression DNA vaccines (pCSm-AAL and pCSm-BAA) which encode GTPV structural proteins corresponding to the Vaccinia virus proteins A27, L1, A33, and B5, respectively, were constructed. Then, theirs ability to induce humoral and cellular response in mice and goats, and protect goats against virulent virus challenge were evaluated. The results showed that, vaccination with pCSm-AAL and pCSm-BAA in combination could elicit strong humoral and cellular responses in mice and goats, provide partial protection against viral challenge in goats, and reduce disease symptoms. Additionally, priming vaccination with the above-mentioned DNA vaccines could significantly reduce the goats' side reactions from boosting vaccinations with current live vaccine (AV41), which include skin lesions at the inoculation site and fevers. Data obtained in this study could not only facilitate improvement of the current goatpox vaccination strategy, but also provide valuable guidance to suitable candidates for evaluation and development of orthopoxvirus vaccines.
Goatpox, caused by goatpox virus (GTPV) belonging to the genus Capripoxvirinae in the family Poxviridae, is an acute feverish and contagious disease in goats. This disease is characterized by fever, generalized skin nodules, lesions in the respiratory and gastrointestinal tracts, and lymph node enlargement (Kitching, 2004; Kitching and Carn, 2004) . GTPV has a genome of approximately 149 kbp typically encoding more than 140 proteins. Similar to Orthopoxviruses, maturation of GTPV during the viral life cycle results in two major infectious forms of virus, intracellular mature virus particles (IMV) and extracellular enveloped virus particles (EEV), which have different repertoires of viral envelope proteins (Moss, 2001 (Moss, , 2006 .
GTPV is endemic in Africa north of the Equator, the Middle East, the Indian subcontinent, and parts of the People's Republic of China. As the most serious poxvirus disease of production animals, goatpox causes high mortality and significant economic losses, thereby posing a major obstacle to international trade. Accordingly, goatpox is categorized as a notifiable disease by the World Organization for Animal Health (OIE) (Kitching, 2004; Kitching and Carn, 2004; Bowden et al., 2008) . Both live attenuated and inactivated vaccines are available in the prevention and control of goatpox. Inactivated vaccines provide only shortterm immunity. Although highly immunogenic and longer term immunoprotection is offered by live attenuated vaccines, some issues remain to be solved, including risk of virulence reversion, and difficulty in distinguishing vaccinated animals from infected ones. Therefore, the use of live virus vaccines in nonendemic countries may not be desirable (Kitching, 2003; Bowden et al., 2008) .
The Kenyan vaccine strain of sheeppox virus and GTPV is used most widely in the world, originally isolated from a sheep, and is possibly related to lumpy skin disease virus (Kitching et al., 1987) . Majority of sheep and goats vaccinated with the Kenyan isolate developed neither detectable anti-capripoxvirus antibodies nor clinical disease symptoms associated with capripoxvirus infection. However, they were protected from subsequent infection from other capripoxviruses (Babiuk et al., 2009) . GTPV-AV41, the live attenuated GTPV vaccine strain used widely in China, also has good immunogenicity. Recently, however, increasing reports have shown that it may cause dangerous complications, including generalized skin nodules and misbirth in native breed goats in southern China, imported pure breeds, and outbreds (Huang and Wei, 2004; Li et al., 2005; Zhao et al., 2005) . Accordingly, it is necessary to develop a safer and more effective Contents lists available at ScienceDirect Virology j o u r n a l h o m e p a g e : w w w. e l s e v i e r. c o m / l o c a t e / y v i r o alternative approach to improve the current goatpox vaccination strategy.
One strategy to reduce virus-associated complications is not to vaccinate with the whole live virus, but instead with components of the virus known to induce protective immunity. Several Vaccinia virus (VACV) IMV envelope proteins have been identified as targets of neutralizing antibodies, including A27, L1, H3, and D8 proteins (Davies et al., 2005; Hsiao et al., 1999; Ichihashi and Oie, 1996; Lin et al., 2000; Rodriguez et al., 1985; Wolffe et al., 1995) . Furthermore, antibodies against B5 protein neutralize EEVs (Bell et al., 2004) , and antibodies against A33 are protective in vivo even though they do not elicit neutralizing antibodies (Galmiche et al., 1999) . Both DNA and recombinant protein vaccines using these individual outer membrane proteins of vaccinia virus elicited protective antibody responses in mouse and non-human primate models (Fogg et al., 2004; Hooper et al., 2004) . Moreover, polyvalent formulations with various combinations of the four poxvirus antigens (A27, L1, B5, and A33) achieved better protection than a monovalent formulation using only one of these antigens (Hooper et al., 2003 , 2004 , Fogg et al., 2004 .
The purpose of this work is to investigate the effectiveness of Semliki forest virus (SFV) replicon-based DNA vaccines as novel, non-transmissible GTPV vaccines. The results show that immunization in combination with two DNA vaccines comprising A27, L1, A33, and B5 GTPV homologues could elicit immunized mice and goats to produce specific humoral and cellular responses. This not only provided partial protection against lethal GTPV challenge and reduced the severity of disease lesions, but also significantly reduced pathogenicity of the live attenuated vaccine GTPV-AV41 in goats without affecting their immunogenicity.
Results

Construction and determination of the expression vector pCSm
An 8.0-kb fragment containing the replicon encoding regions and a 26S promoter of SFV was inserted into the EcoRV-SpeI site of pIRESneo1, and the expression plasmid pCSm was obtained after another 0.27-kb SmaI-EcoRV fragment was subsequently inserted to supplement the first part of the SFV genome (Fig. 1) . To determine the expression activity of pCSm, the EGFP gene was inserted into pCSm and pCS. The resulting plasmids, pCSm-EGFP and pCS-EGFP, were then transfected into BHK-21 cells using Lipofectamine 2000 reagent. After incubation at 37°C for 48 h, cells were observed under a fluorescence microscope. Results showed that pCSm-EGFP transfected cells could express green fluorescent protein, and the numbers of positive expressing cells and expression amounts in pCSm-EGFP transfected cells were approximately 10-fold higher than those in pCS-EGFP transfected cells (Supplement Fig. 1 ).
Cloning of GTPV genes and construction of expression plasmids
Using the primer pairs listed in Table 1 , the GTPV A27L, L1R, A33R, and B5R orthologous genes from GTPV-AV41 were PCR amplified and sequenced, and the resulting sequences were submitted to Genbank (accession number: EU024477-EU024480). These genes were subsequently cloned into expression plasmid pCSm to create constructs pCSm-A27, pCSm-L1, pCSm-A33, and pCSm-B5. A27L and B5R were linked in frame with L1R and A33R using a FMDV 2A short peptide coding sequence to generate the two expression cassettes A27L-2A-L1R and B5R-2A-A33R, respectively. Further, the two bicistronic expression plasmids pCSm-AAL and pCSm-BAA were obtained (Fig. 1, Supplement Fig. 2 ).
Western blot analysis was performed to evaluate the expression products. The predicted 17 kDa, 27 kDa, 22 kDa, and 26 kDa proteins were expressed in pCSm-A27, pCSm-L1, pCSm-A33, and pCSm-B5 transfecting cells, respectively (Fig. 2) . In addition to 17 kDa and 27 kDa, a 45-kDa protein band was observed in the pCSm-AAL expression product (Fig. 2) . It was presumed to be the un-cleavaged polyprotein of A27-2A-L1. Similarly, an additional 49-kDa band (putative polyprotein of B5-2A-A33) was also observed in the pCSm-BAA expression product (Fig. 2) .
Specific reaction antibodies
To determine the immunogenicity of the expression products, groups of ten mice each were vaccinated intramuscularly with the above-mentioned six DNA plasmids constructs, respectively (Experiment 1). The mice were vaccinated at days 0 and 21. As a positive control, ten mice were vaccinated intramuscularly with GTPV-AV41. Sera were collected weekly after vaccination, and an equal volume of sera from individual mice from the same groups was mixed and tested for the presence of antibodies against GTPV, A27, A33, or B5.
As shown in Fig. 3A and Table 1 , specific antibody titers of recombinant plasmids and virus vaccinated mice increased dramatically on DPI 7, and continued to increase after the boost. On DPI 35, GTPV-specific and A27-specific antibody titers of pCSm-AAL and pCSm-AAL + pCSm-BAA vaccinated mice were as high as or 2-fold higher than those of virus vaccinated mice (12,800:12,800 and 12,800:6400, respectively), as measured by GTPV-infected-cell-lysate or A27-specific ELISA. Moreover, A33-specific and B5-specific antibody titers of pCSm-BAA and pCSm-AAL + pCSm-BAA vaccinated mice were 8-fold higher than those of virus vaccinated mice (12,800:1600), measured by A33-specific or B5-specific ELISA.
Further, two groups of four goats each were inoculated intramuscularly with pCSm-AAL + pCSm-BAA (Experiment 2). On DPI 21, one group was boosted with the same dose; the other group and another four goats were injected intradermally with GTPV-AV41. Sera were also collected weekly and tested for specific antibodies. Similarly, goats inoculated with DNA vaccine developed specific antibodies on DPI 7, and these increased after the boost (Fig. 3B) . On DPI 42, GTPV-specific antibody titers of the DNA + virus and virus vaccinated group were highest (25,600, Table 2 ), and were 2-fold higher than those of the DNA vaccinated group (12,800); however, A27-, A33-, and B5-specific antibody titers of the virus vaccinated group were lower than those of the DNA and rDNA/virus vaccinated groups (6400:25,600:12,800, 6400:25,600:12,800, and 6400:12,800:12,800, respectively). Interestingly, compared to the DNA or virus vaccinated groups, antibody titer increases in the rDNA/virus group were postponed at least 1 week directly after the boosting vaccination; however, its titers still met or exceeded the level of the virus vaccinated group on DPI 42 (Fig. 3B ).
GTPV-specific neutralizing antibody responses
GTPV-specific neutralizing antibodies in sera from mice and goats were measured by a modified neutralization assay based on observation of green fluorescent protein using the EGFP expressing recombinant GTPV, vTK-EGFP.
Paralleling that of the ELISA antibodies, mice vaccinated with recombinant plasmids or viruses developed neutralizing responses on DPI 14, and continuously increased after boosting. On DPI 35, GTPVspecific neutralizing antibody titers of pCSm-AAL + pCSm-BAA and virus vaccinated mice were highest (35 and 32); followed by those of pCSm-A27, pCSm-L1, and pCSm-A27 + pCSm-L1 (range 22-25). Those of pCSm-A33, pCSM-B5, and pCSm-A33 + pCSM-B5 were lowest (range 12-16).
Similarly, goats vaccinated with DNA vaccine developed neutralizing antibodies on DPI 14, and these increased after the boost. As shown in Table 2 and Supplement Fig. 3 , on DPI 42, neutralizing antibody titers of DNA + virus vaccinated group (mean= 50.5) were higher than those of the virus group (mean = 43.3) and the DNA group (mean= 38.3).
Specific T-lymphocyte proliferation responses
Specific T-lymphocyte proliferation responses of mice and goats were measured by MTT assay. SI values higher than 1.5 indicated a positive response. As shown in Fig. 4 , except for the SI mean of pCSm-B5 individually vaccinated mice had values lower than 1.5 when simulated with GTPV-infected-cell-lysate, mice and goats vaccinated with other DNA vaccines or virus all developed GTPV-specific (simulated with GTPV-infected-cell-lysate) and protein-specific (simulated with individual recombinant protein) T-lymphocyte proliferation responses (SI mean ranges of mice and goats were 1.53-3.29 and 2.11-3.60, respectively). The highest SI value was observed in samples from both mice and goats simulated with A33 protein. Analysis of each individual antigen-specific T-lymphocyte proliferation response of mice showed no difference (P N 0.05) between the pCSm-AAL + pCSm-BAA group and all other individual DNA vaccinated groups. Moreover, each individual antigen-specific Tlymphocyte proliferation response of goats vaccinated with DNA vaccine was lower (P b 0.01) than those of the virus group, whereas those of the rDNA/virus group met (P N 0.05) those of the virus group.
Specific IFN-γ responses in mice
On DPI 35, antigen-specific IFN-γ responses of mice were tested by IFN-γ ELISPOT using GTPV-infected-cell-lysate or recombinant proteins as a simulator, respectively. As shown in 
DNA prime vaccination alleviated side reaction of live virus vaccination
On DPI 21, group of goats pre-injected with pCSm-AAL+ pCSm-BAA (group 2.2) or PBS (group 2.3), were inoculated intradermally with GTPV-AV41 and observed for clinical signs of side reactions. As shown in Figs. 6, 7 and Table 3 , from 3 days post virus inoculation, four goats in the PBS/virus group developed apparent skin lesions with diameters of 1-2 cm at the site of inoculation, and fevers with a mean highest temperature of 39.9 ± 0.4°C (2/4 temperatures exceed 40°C); however, goats in the rDNA/virus group did not experience fever onset (39.4 ± 0.2°C) until 5 days post virus inoculation, and only two of four goats developed small skin lesions with diameters of 0.5-1 cm. Moreover, the fever duration of the rDNA/virus group was 1-2 days shorter than that of the PBS/virus group. This suggests that DNA prime vaccination can, to some extent, alleviate the side reactions of live virus vaccination.
Viral challenge results of goats with GTPV-AV40
On DPI 42, goats were challenged with 1000 SID 50 standard virulence strain GTPV-AV40. As expected, goats in the rDNA/virus Equal volume of sera from individual mice from the same groups was mixed and tested for the presence of specific reaction antibodies against GTPV, A27, A33, or B5 by I-ELISA, and neutralizing antibodies against GTPV by using a modified neutralization assay based on observation of green fluorescent protein. Table 4 , on DPC 4, control group goats developed fevers (mean highest temperature = 41.4 ± 0.3°C) and typical goatpox clinical symptoms, including stage I skin erythematous papule (mean diameter = 3.3 ± 0.7 cm) formation at the inoculation site.
And from DPC 7, the behavior and appetite statuses of all goats became worse (4/4), and multiple stage II skin lesions developed at the noninoculation sites. By contrast, goats in the DNA vaccinated group also showed relatively low fever responses (mean highest temperature = 40.7 ± 0.2) and stage I skin papules with approximately half the size of the control group goats (mean diameter = 1.9 ± 0.4 cm).
Behaviors and appetites in this group were better than those in the control group. Moreover, only one goat developed stage II skin lesions. To further assess the protection efficacy of the two DNA vaccines, all goats were euthanized and necropsied on DPC 10. No goatpoxspecific pathological lesions or GTPV-specific nucleic acids were found in the rDNA/virus vaccinated group or virus group. Sporadic nodular enanthems could be found in the lungs (4/4) and abomasum (1/4) of control goats ( Supplement Fig. 4) ; and 413 bp GTPV-specific nucleic acids could also be found by PCR assay in the lung (4/4), abomasum (2/4), liver (2/4), kidney (2/4), spleen (2/4), and draining lymph node (2/4) samples. In contrast, sporadic nodular enanthems were observed in the lungs of only one goat in the DNA vaccinated group, and GTPV nucleic acids were found in the lungs of two goats.
Additionally, infectious viruses were isolated and titrated from skin lesion samples and PCR positive lung samples of the control group and DNA vaccinated group. Results showed mean viral titers from skin lesions and lung samples of the DNA vaccinated group were 10 4.4 TCID 50 /g and 10 5 TCID 50 /g, respectively, which were 4-and 10-fold lower than those of the control group (10 5 TCID 50 /g and 10 6 TCID 50 /g, respectively). Thus, DNA vaccination provided partial protection against viral challenge, and reduced disease severity, viral growth, and dissemination in hosts. Moreover, DNA prime vaccination alleviated pathogenicity of the boosting vaccination using the live vaccine (AV41) on goats, but did not affect the immunogenicity of live vaccine.
Discussion
Due to the concerns of safety risks and possible vaccination side effects with attenuated live GPTV vaccines, it is desired to explore 
Equal volume of sera from individual goats from the same groups was mixed and tested for the presence of specific reaction antibodies against GTPV, A27, A33, or B5 by I-ELISA. However, neutralizing antibodies against GTPV were measured one by one using a modified neutralization assay. a Arithmetic mean value. alternative vaccine strategies with better safety and efficacy (Huang and Wei, 2004; Li et al., 2005; Zhao et al., 2005) . Recent studies have demonstrated the feasibility of developing subunit-based smallpox vaccines. Both DNA and recombinant protein vaccines using individual outer membrane proteins of VACV elicited protective antibody responses in small animal and non-human primate models. Little data exists on the key protective antigens of capripoxviruses; most available information is based on the VACV model. In this study, we attempt to develop an alternative DNA vaccine strategy which expresses GTPV structural proteins corresponding to the Vaccinia virus proteins A27, L1, A33, and B5, and investigate their potential as vaccine candidates against GTPV in goats.
To overcome conventional DNA vaccine low protein expression and immunogenicity, a new generation of mammal cell expression vector systems based on the replicon of alphaviruses, including SFV, Sindbis virus (SINV), and Venezuelan equine encephalitis virus (VEEV), has recently been developed. These vectors have shown great potential as gene delivery vehicles for various applications in cancer gene therapy and vaccine development. For example, Thornburg et al. (2007) successfully developed a potential anti-cowpox virus vaccine based on replicon particles of VEEV (VRP). However, the primary technical drawback of the above-mentioned original alphavirus systems is that they require production and manipulation of recombinant RNA in vitro. To address this problem, more recently researchers have made some modifications in original alphavirus expression vectors, resulting in new DNA-based vectors without the need of in vitro transcription.
These so-called alphavirus replicon-based DNA vaccines, or suicidal DNA vaccines, simplify the use of alphaviruses in vaccine delivery, but retain most merits of the alphavirus vector, which include high level heterologous protein expression and which elicit strong immune response and apoptosis. Therefore, in this study we introduced an SFV replicon into the commercial eukaryotic vector pIRESneo, resulting in a new vector (pCSm) without the need of in vitro transcription, and then constructed a series of replicative plasmid DNA encoding the GTPV structural proteins. The resulting plasmids all possessed good protein expression levels both in vivo and in vitro.
It was previously demonstrated that vaccination with a combination of IMV and EEV genes (A27, L1, B5, and A33, respectively) protected animals from challenge more effectively than vaccination with either gene alone. In almost all reported research to date, however, only DNA plasmids expressing individual antigens have been constructed. An obvious drawback is that researchers need to prepare and inoculate several DNA plasmids, which is laborious and inefficient. Thus, in addition to DNA plasmid expressing individual proteins, we also generated two bicistronic expression DNA constructs. Currently, many researchers prefer to imitate a co-expression strategy used by many viruses: to express several proteins as a polyprotein, then use proteinases to cleavage it into separated proteins (de Felipe et al., 1999; Furler et al., 2001; Szymczak et al., 2004) . In this study, we used a small peptide of 18 amino acids (2A) from the foot-and-mouth disease virus (FMDV) to avoid the need for proteinases to process the polyprotein. FMDV 2A was introduced as a linker between A27 and L1, or B5 and A33, to allow for autonomous intraribosomal self-processing of polyproteins. As Western blot analysis revealed, four proteins were correctly expressed and processed. Considering manipulation convenience and transcription efficiency limitations of the promoter, we did not construct tertcistronic in this study, although this would be possible in theory. It should be noted that un-cleavaged polyproteins were found in the expression products. Three possible reasons explain this phenomenon: (1) affection from the special amino acid sequence or structure domain at the upstream and downstream of 2A polypeptide in the polyproteins; (2) high output of protein precursors; or (3) other infectors, including cell lines. The same phenomenon has been reported previously by Mattion et al. (1996) and Donnelly et al. (1997) . Taken together, our data provide additional evidence to support the FMDV 2A sequence as a useful tool to allow for coexpression of multiple proteins from a single vector.
As expected, the magnitude of GTPV-specific reaction antibodies and neutralizing antibodies both in mice and goats followed the order pCSmAAL + pCSmBAA/virus N Virus ≥ pCSmAAL + pCSmBAA N pCSmAAL N pCSmL1 N pCSmA27 N pCSmBAA N pCSmA33 N pCSmB5, measured by GTPV-infected-cell-lysate ELISA and viral neutralization test. It should be noted that the virus neutralization assay used in this study primarily measures antibodies that neutralize IMV but not EEV; however, we do observed typical comet-shaped plaque formation in vTK-EGFP infected LK cells and comet reduction phenomenon when existing A33-or B5-specific antibodies. Thus, the weak inhibition abilities of A33 and B5 sera may be attributed to the presence of anti-EEV neutralizing antibodies.
It is generally accepted that the immunity to capripox infection is predominantly cell-mediated. Therefore, in this study we also evaluate the ability of individual protein to elicit the specific cellular response. When simulated with individual purified proteins, we found that the magnitude of antigen-specific T-lymphocyte proliferation responses and IFN-γ responses followed the order A33 N B5 N A27. It suggested that EEV proteins (A33 and B5) may play more role than IMV proteins on cell-mediated response against GTPV.
Overall, our results showed that two GTPV IMV proteins (A27 and L1) and two EEV proteins (B5 and A33) were able to elicit specific antibodies and cell-mediated responses in both mice and goats, and combinations of these four proteins afforded stronger immune responses. These results are in good agreement with those of other researchers (Hooper et al., 2003 (Hooper et al., , 2004 Fogg et al., 2004) .
Other GTPV structural proteins may also be potential candidate antigens and should be included in the final multivalent DNA-based or subunit-based GTPV vaccine. For example, Carn et al. (1994) previously demonstrated that a subunit vaccine made from a GTPV H3 homolog could also induce a specific neutralizing antibody, as well as reduce disease severity and limit local virus spread. This suggests that H3 is a potential protective antigen of GTPV. However, we did not examine H3 in this study due to conflicting results obtained from various researches on its VACV counterpart. Results from Pulford et al. (2004) showed that H3L failed to elicit neutralizing antibody towards VACV and afforded limited protection (33%), whereas more recently Davies et al. (2005) found that mice inoculated with purified H3 protein developed high titer VACV-neutralizing antibodies and all survived from challenge with one 50% lethal dose VACV NYBOH . Furthermore, D8, A56, and A36 were also found to potentially serve as key vaccine components (Pulford et al., 2004) .
Compared to one single live virus immunization providing complete protection against viral challenge, two immunizations of multivalent formulations comprising two DNA vaccines could only provide partial protection. Our results parallel previous reports on mice and non-human primates (Hooper et al., 2003 (Hooper et al., , 2004 Fogg et al., 2004; Fang et al. 2006; Sakhatskyy et al., 2006) . Improving the immunization strategy and co-expressing cytokine or a co-stimulating factor such as IL-2, IFN, or GM-CSF may enhance the protective efficacy of DNA vaccines. Particularly, the delivery system for SFV replicon-based DNA vaccines should be optimized for their large molecular weight (exceeding 12 kb). Gene guns may serve as effective administration tools to enhance the immunization effect of DNA plasmids (Hooper et al., 2007) . However, their high-cost and need for a pre-coat DNA with gold particles make it unsuitable for clinical veterinary practice. Recently, Chitosan derivative nanoparticles and trehalose dimycolate were both explored as potential DNA vaccine carriers and adjuvants (Khatri et al., 2008; de Paula et al., 2007) . Subsequent studies will investigate these delivery systems and adjuvants, as well as various immunization doses and frequencies.
In this study we demonstrated that, although GTPV-DNA vaccines did not afford complete protection to goats from virulent challenge, priming the vaccination with GTPV-DNA vaccines could significantly reduce the goats' side reactions from boosting vaccinations with live vaccine (AV41), which include skin lesions at the inoculation site and fevers. In this context, the DNA primer would immunologically attenuate the subsequent live vaccine boost. Moreover, our results showed that, although the rDNA/virus group antibodies increased The "−" indicates no symptoms.
relatively slowly immediately after live virus inoculation, the humoral responses and cellular responses of goats in this group still reached the highest levels among all groups on DPI 42. This suggests that GTPV-DNA vaccines also ultimately enhance the immune effect of the live virus vaccine. Thus, our study supports the possibility of improving the safety of the current GTPV vaccine by prime immunizing with GTPV-DNA vaccines, which enhance immunity prior to exposure to live GTPV, and thereby lower the risk of potential complications.
The threat of bioterrorist attacks and natural zoonotic orthopoxviral (e.g., monkeypox virus) outbreaks provide the impetus for renewed efforts to develop safe and effective alternative smallpox vaccines or antiviral drugs. Bowden et al. (2008) recently found that the pathogenesis and tissue tropism of capripoxvirus infections in sheep and goats were in marked contrast to those seen with ectromelia virus in mice, and instead more closely resembled those of smallpox and monkeypox. This suggests that goatpox or sheeppox could be more satisfactory surrogate animal models for smallpox or monkeypox than traditional rodent models. Therefore, data obtained in our study could not only facilitate improvement of the current goatpox vaccination strategy, but also provide valuable guidance to suitable candidates for evaluation and development of orthopoxvirus vaccines.
In summary, we showed that SFV replicon-based DNA vaccines encoding GTPV structural proteins of IMV and EEV, could elicit strong humoral and cellular responses in mice and goats, provide partial protection against viral challenge in goats, and reduce disease symptoms. Additionally, priming vaccination with the above-mentioned DNA vaccines and boosting with live virus could improve the efficacy and safety of the current live GTPV vaccine. Optimal inoculation dosage and frequency, along with rational adjuvants, will be explored in future studies.
Materials and methods
Viruses and cells
GTPV live attenuated vaccine strain AV41 and standard virulence strain AV40 were introduced from the China Institute of Veterinary Drug Control (CIVDC, Beijing) and maintained in secondary bovine testis (SBT) cell monolayers grown in Eagle minimal essential medium containing 10% heat-inactivated fetal bovine serum and 1% antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin). A recombination GTPV expressing green fluorescent protein, vTK-EGFP, was constructed previously by ourselves (unpublished) and was also maintained in SBT cells and African green monkey kidney (Vero) cells. Baby hamster kidney (BHK-21) cells were used for transient expression experiments.
Construction of SFV replicon-based expression plasmid pCSm
Adapted from the method illustrated by DiCommo and Bremner (1998) , the plasmid pCSm was built in two stages: (i) Eukaryotic Expression Vector pIRESneo1 (Clontech, USA) was digested with EcoRV and XbaI, and was ligated with an 8.0-kb EcoRV-SpeI fragment from pSFV1 containing the replicon encoding regions and a 26S promoter of SFV; and (ii) the resulting plasmid, pCS, was cut with EcoRV and ligated with a 0.28-kb SmaI-EcoRV fragment containing the first part of the SFV genome (generated by amplification and digestion of base pairs 1-279 in pSFV1 with the primer O-SFV1 (SmaI and EcoRI): 5′-ttcccggggaattcatggcggatgtgtgacat-3′ and reverse primer O-SFV2: 5′-gtacagcgatgttggtgc-3′). The resulting plasmid, pCSm, contained a cytomegalovirus intermediate-early promoter/enhancer and bovine growth hormone poly adenylation-termination signal upstream and downstream of the SFV replicon and 26S promoter region, respectively.
Cloning of GTPV genes
The GTPV A27L, L1R, A33R, and B5R orthologous genes were PCR amplified from GTPV-AV41 using Ex-Taq DNA polymerase (Takara Bio., Dalian, China) with the primer pairs listed in Table 5 . Amplicons were cloned into the pMD18-T simple vector (Takara Bio., Dalian, China) for sequencing.
Construction and preparation of GTPV antigen-expressing vectors
The resulting GTPV genes were individually digested by BamHI and SmaI, and inserted into the expression vector pCSm to generate the four single expression plasmids pCSm-A27, pCSm-L1, pCSm-A33, and pCSm-B5.
Meanwhile, a 0.3-kb fragment containing a 2A short peptide encoding region was amplified by the primer 2A1 (XbaI): 5′-ctctaga-ACTTTGAACTTTGATCTACTC-3′ and 2A2 (SmaI): 5′-acccgggGCGCCC-AATACGCAAAC-3′ from a plasmid pMD-VP12A comprising the VP1 gene and 2A gene of FMDV O/NY00. The 2A fragment was subsequently inserted into pMD-A27 and pMD-B5 digested similarly with the BamHI and SmaI, in frame with the A27L or B5R genes. The resulting plasmids pMD-A272A and pMD-B52A were cut using BglII (this digestion site was introduced immediately downstream of the 2A gene during the construction of pMD-VP12A) and XbaI, and inserted by the BamHI-XbaI fragments of L1R and A33R, respectively, to generate the two expression cassettes A27L-2A-L1R and B5R-2A-A33R. Finally, two bicistronic expression plasmids, pCSm-AAL and pCSm-BAA, were obtained by cloning A27L-2A-L1R and B5R-2A-A33R into the BamHI-SmaI site of pCSm, and sequenced to establish an intact and representative open reading frame.
Plasmid DNA was prepared in bulk from suitable clones using an endotoxin-free mega prep kit (Qiagen, Germany) and DNA was resuspended in sterile PBS. DNA concentrations were determined by UV spectroscopy.
Expression and purification of GTPV A27, A33, and B5 orthologous proteins
To produce GTPV antigen protein for measuring the levels of humoral and cellular response in vitro assays, the entire A27L coding region was PCR amplified using the primer pairs listed in Table 1 , and cloned into the pET32a vector (Novagen, Germany) in frame with the 5′ purification tag sequences (S-and His-Tags). Fragments of the gene encoding the ectodomain of A33R and B5R were similarly amplified and cloned into the pET32a vector.
The recombinant proteins were produced, according to the manufacturer's instructions, in Escherichia coli BL21 (DE3) and purified using TALON IMAC resin (Clontech, USA). The "−" indicates no symptoms.
Transient expression
Plasmid DNA was transfected into BHK-21 cell monolayers (90% confluent) using Lipofectamine 2000 reagent (Invitrogen, USA) according to the manufacturer's instructions. After 48 h, the total cellular lysates were prepared with lysis buffer (10 mM Tris-Cl, pH 7.4, 1 mM MgCl 2 , 0.5% NP40, 20 μg/ml DNase I) and electrophoresed through an SDS-10% polyacrylamide gel. The proteins were then transferred onto nitrocellulose membranes (Bio-Rad, USA). Membranes were incubated with anti-GTPV positive sera at a dilution of 1:500. Bound antibody was detected by incubation of the membrane with rabbit anti-goat IgG antibodies labeled by the alkaline phosphatase at a dilution of 1:2000, followed by visualizing with NBT/BCIP substrates (Promega, USA).
Vaccines and vaccination
Mouse vaccination
Ninety BALB/c mice were separated into nine groups. Group 1.1, 1.2, 1.3, 1.4, 1.5, and 1.6 were vaccinated with 100 μg of pCSm-A27, pCSm-L1, pCSm-A33, pCSm-B5, pCSm-AAL, and pCSm-BAA in 0.1 ml of phosphate-buffered saline (PBS), respectively. Group 1.7 was vaccinated in combination with 100 μg pCSm-AAL and 100 μg pCSm-BAA. Group 1.8 was injected with 1 × 10 5 TCID 50 of GTPV-AV41 in 0.1 ml of PBS, and group 1.9 was injected with 100 μg of pCSm as a control. All groups were boosted with an equivalent dose at day post-inoculation (DPI) 21, respectively. Vaccines were injected by inserting a needle and syringe into the tibialis cranialis muscle of hind legs.
Goat vaccination
Sixteen unvaccinated healthy, seronegative 8-month-old crossbreeding dairy goats were separated into four groups. Groups 2.1 and 2.2 were vaccinated simultaneously with 500 μg pCSm-AAL and 500 μg pCSm-BAA by intramuscular (IM) inoculation. Group 2.3 was injected with 1 ml PBS, and group 2.4 was injected intramuscularly with 500 μg pCSm in 0.5 ml of PBS. On DPI 21, group 2.1 and group 2.4 were boosted with an equivalent dose, respectively; group 2.2 and 2.3 were inoculated intradermally with 0.2 ml of reconstituted commercial live vaccine (Jilin Zhengye Biologicals Co. Ltd., Jilin; containing 1 × 10 4 TCID 50 live GTPV-AV41 per dose) in the caudal fold, as described by the manufacturer. The goats were observed daily and rectal temperature was recorded daily. Animal experiments were carried out in accordance with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines for care and handling of experimental animals.
Evaluation of the humoral immune response to GTPV ELISA Indirect enzyme linked immunosorbent assays (I-ELISA) were performed on mouse and goat serum to measure the amount of anti-GTPV virion or viral protein antibodies present in each sample. Briefly, 96-well flat-bottomed plates (Costar, USA) were coated with formaldehyde-inactivating GTPV-AV41 Vero cell culture lysis, purified recombination protein A27, A33, and B5 (200 ng per well), respectively, in 0.1 M carbonate/bicarbonate buffer (pH 9.6) overnight at 4°C. After being blocked with 5% BSA-PBS, plates were incubated with duplicate 100-fold dilutions of test sera for 1 h at 37°C. Peroxidase-conjugated anti-mouse IgG (or anti-goat IgG) conjugate (Sigma) at 1:4000 dilution was then added for 1 h at 37°C, followed by the substrate (0.01% hydrogen peroxide in phosphate/citrate buffer). The optical density (OD) of the ELISA plate was read at 492 nm. Endpoint titers were determined as the highest dilution with an absorbance value greater than the mean absorbance value from negative control plasmid (pCSm)-vaccinated animals plus three standard deviations.
Neutralization assay
IMV neutralization titers in mice and goat sera were determined by using a modified neutralization assay based on observation of green fluorescent protein. Sera were inactivated at 56°C for 30 min, after which 50 μl of each sample or control serum was added to the well at the end of each row of a 96-well tissue culture plate, and then diluted in a 2-fold serial dilution across the plates. 50 μl of 100 TCID 50 recombinant GTPV, vTK-EGFP, was subsequently added to each well, and the plate was vortexed for 1 min. After incubation at 37°C for 60 min, 100 μl of 10 5 cells/ml SLT cell in Eagle's MEM containing 2% fetal bovine serum was added to each well. After 7 days of incubation at 37°C with 5% CO 2 , plates were observed and the percentage of infected cells was determined by fluorescence microscope. Endpoint titers were expressed as the reciprocal of the final serum dilution that resulted in neutralization of the virus activity by 50%.
T-lymphocyte proliferation assay At 14 days post booster immunization (DPI 35), goat blood was collected in 5 mM EDTA and used immediately for the isolation of peripheral blood mononuclear cells (PBMC) using Lymphoprep (TBD, Tianjin, China). Three mice from each group were killed and splenocytes were isolated using sterile procedures. The goat PBMCs and mouse splenocytes were then resuspended in complete culture medium (RPMI 1640 medium with 10% fetal calf serum). MTT assays were carried out in triplicate cultures of 200 μl (2×10 6 /ml cells) in 96-well flat-bottom plates. Briefly, PBMC or splenocyte were stimulated with 2 μg/ml of recombinant A27, A33 and B5, 1:100 inactivated GTPV-AV41, 1 μg/ml Concanavalin A (ConA; Sigma), respectively. Plates were incubated at 37°C for 45 h, followed by incubation with MTT for 3 h, and then 150 μl DMSO was added to every well to dissolve the deposit. Absorbance was measured at 570 nm and results were expressed as stimulation index (SI) (cpm sample/cpm medium alone).
Murine IFN-γ ELISPOT assay Three mice from each group were sacrificed on DPI 35. The splenocytes were isolated using sterile procedures and resuspended in RPMI 1640 medium with 10% fetal calf serum. Specific IFN-γ response against GTPV was subsequently determined using the mice IFN-γ ELISPOT assay kit (Dakewe Biotechnology Co. Ltd., Shenzhen, China). 96-well PVDF-membrane plates (supplied in kit) were coated with monoclonal antibody to mouse IFN-γ diluted 1/100 in PBS and incubated overnight at 4°C. After several washes with PBS, plates were blocked with complete culture medium for 2 h at room temperature. Mice splenocytes were added in triplicate at an input cell number of 1 × 10 5 cells per well in 100 μl complete culture medium. Table 5 Primer pairs for cloning of GTPV genes.
Primer pairs were designed basing the GTPV strain Pellor genome (accession no. AY077835). Primers included the BamHI (AAATCC), SmaI (CCCGGG) and XbaI (TCTAGA) sites for cloning sequence. And a kozak sequence (CCACCATGG) was inserted into the upper primer to facilitated expressions of the ORFs. The lower primers contained a TTA sequence that codifies for termination of protein translation and a sequence encoding for a poly-histidine sequence at the 3′ side of the termination signal. Recombinant A27, A33, and B5, inactivated GTPV-AV41 were diluted in complete culture medium at a final concentration of 10 μg/ml or 1:100, respectively, and 100 μl dilution were added per well. ConA (5 μg/ml) was used as a positive control, and cells resuspended in complete culture medium only served as a negative control. After an incubation period of 24 h at 37°C, cell cultures were discarded and 200 μl of pre-cold distilled water were added per well followed by incubation at −20°C for 5 min and at 4°C for 5 min. Plates were subsequently washed with PBS and incubated at 37°C for 1 h with 100 μl/well of the biotinylated detector mAb to mouse IFN-γ diluted 1/1000 in PBS supplemented with 1% BSA (PBS+ 1% BSA). Plates were washed and 100 μl/well of streptavidinalkaline phosphatase conjugate, diluted 1/1000 in PBS + 1% BSA, was added and incubated at 37°C for 1 h. The plates were then washed and 100 μl of AEC substrate solution was added per well. The colorimetric reaction was terminated after 30 min at room temperature by washing several times with distilled water. Plates were air-dried and spots were counted using an automated ELISPOT reader system (Bioreader 4000 PRO, Biosys, Germany). The mean number of spots from triplicate wells was adjusted to 1 × 10 6 splenocytes. ELISPOT data are expressed as mean± S.D. The antigen-specific IFN-γ responses were calculated after subtraction of spots formed in control medium wells from the number of spots formed in response to the corresponding stimulator.
Challenge of goats
To determine the mean skin infective dose (SID 50 ) of GTPV-AV40 in goats, 16 seronegative 8-month-old goats were randomly divided into four groups (four per group). The stock GTPV-AV40 was diluted at 10 − 4 , 10 , and 10 − 7 with PBS. Each goat was injected intradermally with 1 ml of the diluted GTPV solution in the abdominal area. Clinical symptoms (i.e., skin macules or papule formation on abdomen, tail, foot, mouth, or nose with body temperature over 41°C) were observed until 14 days after viral challenge (DPC). The goats were diagnosed as goatpox positive in the presence of the above clinical symptoms. The mean skin infective dose that could cause 50% of the goat to become goatpox positive symptoms was designated as 1 SID 50 , which was calculated to be 1 × 10 6.0 /ml.
At 42 days post-initial inoculation, all goats were challenged intradermally with 1000 SID 50 in 0.5 ml in the caudal fold. GTPVpositive goats were determined according to skin lesion appearance and body temperature over 41°C. All goats were kept in separated stalls within one house. After 10 days of observation, the goats were euthanatized and necropsied, any pathological lesions were recorded, and GTPV titers in main organs were determined by virus culture and PCR (Zheng, 2007) .
Statistical analysis
To determine whether immune responses among the groups of animals were significantly different from each other, Student's t-test analysis was performed using Microsoft Excel software and SPSS version 10.0.
